MarketThe Global Nanotechnology Drug Delivery Market was valued at USD 1,232 Million in 2020 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.6% between 2021 to 2028 according to analysts at Vantage Market 10;The nanotechnology drug delivery system is the system of drug delivery system in which the usage of nanoparticles is seen, which holds the potential to act as an effective gene and drug delivery system as mostly used for cancerous treatment. The nanotechnology drug delivery market is driven by the factors such as increasing cancerous scrutiny, and increasing deaths from CVDs also growing research on nanotechnology for cancerous drug development are fueling the market,
Since the outbreak of the COVID-19, widely spread all over the world and has impacted many countries economy and caused huge loses in 10;The nanotechnology drug delivery market is experiencing a negative growth due to unavailability of healthcare facilities because of global health emergency.
The nanotechnology drug delivery market is segmented on the basis of technology and application. The technology segment is further bifurcated into liposomes, micelles, nanocrystals, nanoparticles and others. The nanoparticles sector is holding the largest share and shows potential growth in future forecast. The application segment is divided as Immunology, oncology, neurology, cardiovascular, anti-infective. Based on these the is the oncology sector at having the largest share and potential growth for further forecasted years.
The major players for the nanotechnology drug delivery market are Merck & Co, Johnson & Johnson, Celgene Corporation, Novartis International AG, AbbVie, Roche, Bayer AG, Amgen, and Pfizer.
Regionally, the market is segmented as Asia-Pacific, Europe, North America, the Middle East and Africa and Latin America. North America attained the highest share due to increase in the modernization in healthcare facilities and improved healthcare infrastructure.